{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T06:04:15Z","timestamp":1793340255596,"version":"4.5.0"},"reference-count":82,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ajo.2025.03.025","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T20:09:57Z","timestamp":1742328597000},"page":"99-113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Adherence and Persistence on Prostaglandin Analogues for Glaucoma: A Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"275","author":[{"given":"Christophe","family":"Baudouin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah H.","family":"Van Tassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina A.","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Martinez-de-la-Casa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4464-0877","authenticated-orcid":false,"given":"Alvin","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ajo.2025.03.025_bib0001","article-title":"Epidemiology of glaucoma: the past, present, and predictions for the future","volume":"12","author":"Allison","year":"2020","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.ajo.2025.03.025_bib0002","doi-asserted-by":"crossref","first-page":"148","DOI":"10.18240\/ijo.2021.01.21","article-title":"Sustained-release drug delivery systems for the treatment of glaucoma","volume":"14","author":"Kesav","year":"2021","journal-title":"Int J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2025.03.025_bib0003","doi-asserted-by":"crossref","first-page":"P71","DOI":"10.1016\/j.ophtha.2020.10.022","article-title":"Primary open-angle glaucoma preferred practice pattern\u00ae","volume":"128","author":"Gedde","year":"2021","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2025.03.025_bib0004","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1007\/s40123-023-00831-9","article-title":"Challenging the \u201ctopical medications-first\u201d approach to glaucoma: a treatment paradigm in evolution","volume":"12","author":"Radcliffe","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.ajo.2025.03.025_bib0005","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.2147\/OPTH.S439457","article-title":"Alternatives to topical glaucoma medication for glaucoma management","volume":"17","author":"Bedrood","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.ajo.2025.03.025_bib0006","doi-asserted-by":"crossref","unstructured":"Gallardo M., Smith O., Trubnik V., Reiss G. Interventional glaucoma and the patient perspective. Exp Rev Ophthalmol. 1\u20138. doi:10.1080\/17469899.2024.2382149.","DOI":"10.1080\/17469899.2024.2382149"},{"issue":"986","key":"10.1016\/j.ajo.2025.03.025_bib0007","article-title":"Long-term chronic drop therapy vs. Intracameral procedural pharmaceuticals for glaucoma: what does the evidence support?","volume":"15","author":"Kamat","year":"2024","journal-title":"J Clin Exp Ophthalmol"},{"key":"10.1016\/j.ajo.2025.03.025_bib0008","doi-asserted-by":"crossref","DOI":"10.1097\/j.jcrs.0000000000001537","article-title":"Standalone interventional glaucoma: an evolution from the combination-cataract paradigm","author":"Micheletti","year":"2024","journal-title":"J Cataract Refract Surg"},{"issue":"6","key":"10.1016\/j.ajo.2025.03.025_bib0009","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ophtha.2004.12.035","article-title":"Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review","volume":"112","author":"Olthoff","year":"2005","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2025.03.025_bib0010","doi-asserted-by":"crossref","first-page":"598.e1","DOI":"10.1016\/j.ajo.2005.04.051","article-title":"Persistence and adherence with topical glaucoma therapy","volume":"140","author":"Nordstrom","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2025.03.025_bib0011","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2147\/PPA.S23780","article-title":"Objective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic review","volume":"5","author":"Reardon","year":"2011","journal-title":"Patient Prefer Adher"},{"issue":"Suppl 1","key":"10.1016\/j.ajo.2025.03.025_bib0012","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/ICU.0000000000000953","article-title":"Identifying and addressing common contributors to nonadherence with ophthalmic medical therapy","volume":"34","author":"Hovanesian","year":"2023","journal-title":"Curr Opin Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2025.03.025_bib0013","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1097\/IJG.0000000000000777","article-title":"Comparisons of self-reported glaucoma medication adherence with a new wireless device: a pilot study","volume":"26","author":"Gatwood","year":"2017","journal-title":"J Glaucoma"},{"issue":"1","key":"10.1016\/j.ajo.2025.03.025_bib0014","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13643-019-1014-8","article-title":"Medication adherence influencing factors-an (updated) overview of systematic reviews","volume":"8","author":"Gast","year":"2019","journal-title":"Syst Rev"},{"issue":"9","key":"10.1016\/j.ajo.2025.03.025_bib0015","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.ophtha.2004.02.017","article-title":"Predictive factors for glaucomatous visual field progression in the advanced glaucoma intervention study","volume":"111","author":"Nouri-Mahdavi","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.03.025_bib0016","series-title":"Systematic Reviews: CRD's guidance for undertaking reviews in health care","year":"2008"},{"key":"10.1016\/j.ajo.2025.03.025_bib0017","unstructured":"Kmet L.M., Cook L.S., Lee R.C. Standard quality assessment criteria for evaluating primary research papers from a variety of fields. Edmonton: Alberta Heritage Foundation for Medical Research (AHFMR). AHFMR -HTA Initiative. 13:2004. doi:10.7939\/R37M04F16."},{"key":"10.1016\/j.ajo.2025.03.025_bib0018","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"7109","key":"10.1016\/j.ajo.2025.03.025_bib0019","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"Br Med J"},{"key":"10.1016\/j.ajo.2025.03.025_bib0020","doi-asserted-by":"crossref","unstructured":"Schwarzer G. Meta: an R package for meta-analysis. 2007;7:40-45.","DOI":"10.32614\/CRAN.package.meta"},{"issue":"4","key":"10.1016\/j.ajo.2025.03.025_bib0021","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1183\/09031936.00059814","article-title":"Ageing and the epidemiology of multimorbidity","volume":"44","author":"Divo","year":"2014","journal-title":"Eur Respir J"},{"issue":"1 Suppl","key":"10.1016\/j.ajo.2025.03.025_bib0022","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.ajo.2005.09.011","article-title":"Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data","volume":"141","author":"Wilensky","year":"2006","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2025.03.025_bib0023","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/jop.2008.0072","article-title":"The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence","volume":"25","author":"Zimmerman","year":"2009","journal-title":"J Ocul Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.ajo.2025.03.025_bib0024","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1185\/03007991003659012","article-title":"Physicians' treatment decisions, patient persistence, and interruptions in the continuous use of prostaglandin therapy in glaucoma","volume":"26","author":"Hahn","year":"2010","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"10.1016\/j.ajo.2025.03.025_bib0025","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1442-9071.2007.01564.x","article-title":"Persistency rates for prostaglandin and other hypotensive eyedrops: population-based study using pharmacy claims data","volume":"35","author":"Rait","year":"2007","journal-title":"Clin Exp Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2025.03.025_bib0026","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/eye.2012.294","article-title":"Patterns of adherence behaviour for patients with glaucoma","volume":"27","author":"Cate","year":"2013","journal-title":"Eye (Lond)"},{"issue":"4","key":"10.1016\/j.ajo.2025.03.025_bib48","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/IJG.0b013e31821dac86","article-title":"Determinants of medication adherence to topical glaucoma therapy","volume":"21","author":"Dreer","year":"2012","journal-title":"J Glaucoma"},{"key":"10.1016\/j.ajo.2025.03.025_bib0027","first-page":"1","article-title":"Psychometrics of a new questionnaire to assess glaucoma adherence: the glaucoma treatment compliance assessment tool (an American Ophthalmological Society Thesis)","volume":"111","author":"Mansberger","year":"2013","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"12","key":"10.1016\/j.ajo.2025.03.025_bib49","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1136\/bjophthalmol-2019-315436","article-title":"Acceptability, adherence and economic analyses of a new clinical pathway for the identification of non-responders to glaucoma eye drops: A prospective observational study","volume":"104","author":"Waterman","year":"2020","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2025.03.025_bib0028","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/jop.2016.0052","article-title":"Comparison of self-reported and objective adherence to antiglaucoma medications","volume":"32","author":"Zarnowski","year":"2016","journal-title":"J Ocul Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ajo.2025.03.025_bib50","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/aos.15715","article-title":"Persistence and adherence with Latanoprost: A Danish register-based cohort study in older patients with glaucoma","volume":"102","author":"Amiri","year":"2023","journal-title":"Acta Ophthalmol (Oxf)"},{"issue":"4","key":"10.1016\/j.ajo.2025.03.025_bib51","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1093\/fampra\/cmu031","article-title":"Factors associated with adherence to glaucoma pharmacotherapy in the primary care setting","volume":"31","author":"Castel","year":"2014","journal-title":"Fam Pract"},{"issue":"1","key":"10.1016\/j.ajo.2025.03.025_bib0035","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2021-000921","article-title":"Medicine treatment of glaucoma in Australia 2012-2019: prevalence, incidence and persistence","volume":"6","author":"Daniels","year":"2021","journal-title":"BMJ Open Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2025.03.025_bib52","first-page":"1001","article-title":"Comparison of prostaglandin analog treatment patterns in glaucoma and ocular hypertension","volume":"25","author":"Heo","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"issue":"12","key":"10.1016\/j.ajo.2025.03.025_bib53","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1001\/jamaophthalmol.2014.3333","article-title":"Persistence of topical glaucoma medication a nationwide population-based cohort study in Taiwan","volume":"132","author":"Hwang","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ajo.2025.03.025_bib54","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.2147\/PPA.S367443","article-title":"Clinical practice management of primary Open-Angle glaucoma in the United States: An analysis of Real-World evidence","volume":"16","author":"Imperato","year":"2022","journal-title":"Patient Prefer Adher"},{"issue":"2","key":"10.1016\/j.ajo.2025.03.025_bib55","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2165\/11539460-000000000-00000","article-title":"Persistence with prostaglandin agonist use with and without adjunctive therapy for glaucoma patients: A Canadian population-based analysis","volume":"4","author":"Iskedjian","year":"2011","journal-title":"Patient"},{"issue":"8","key":"10.1016\/j.ajo.2025.03.025_bib56","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.3390\/ijerph18084106","article-title":"Medication adherence and persistence of open-angle glaucoma patients in korea: A retrospective study using national health insurance claims data","volume":"18","author":"Jang","year":"2021","journal-title":"Int J Environ Res Public Health."},{"issue":"1","key":"10.1016\/j.ajo.2025.03.025_bib57","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s10384-013-0284-2","article-title":"Persistence with topical glaucoma therapy among newly diagnosed Japanese patients","volume":"58","author":"Kashiwagi","year":"2014","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.ajo.2025.03.025_bib58","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ajo.2018.01.011","article-title":"Eye drop dispenser type and medication possession ratio in patients with glaucoma: Single-Use containers versus Multiple-Use bottles","volume":"188","author":"Na","year":"2018","journal-title":"Am J Ophthalmol."},{"issue":"6","key":"10.1016\/j.ajo.2025.03.025_bib59","first-page":"e101","article-title":"Adherence and persistence of bimatoprost in prior latanoprost users","volume":"8","author":"Patel","year":"2016","journal-title":"Am J Pharm Benefits"},{"issue":"5","key":"10.1016\/j.ajo.2025.03.025_bib60","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/archophthalmol.2010.345","article-title":"Persistence of patients receiving topical glaucoma monotherapy in an Asian population","volume":"129","author":"Quek","year":"2011","journal-title":"Arch Ophthalmol."},{"issue":"7","key":"10.1016\/j.ajo.2025.03.025_bib61","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1136\/bjo.2010.188607","article-title":"Persistence of glaucoma medical therapy in the Glasgow glaucoma database","volume":"95","author":"Rahman","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2025.03.025_bib62","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ajo.2016.05.001","article-title":"Predictors, Resource Utilization, and Short-term Costs of Laser Trabeculoplasty Versus Medication Management in Open-Angle Glaucoma","volume":"168","author":"Schultz","year":"2016","journal-title":"Am. J. Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2025.03.025_bib63","first-page":"808","article-title":"Predictors of nonadherence to topical intraocular pressure reduction medications among medicare members: A claims-based retrospective cohort study","volume":"22","author":"Sheer","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"10.1016\/j.ajo.2025.03.025_bib64","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1089\/jop.2020.0096","article-title":"Adherence and persistence with First-Line therapy and compliance with glaucoma guidelines using japanese health Care\/Pharmacy claims database","volume":"37","author":"Shirai","year":"2021","journal-title":"J Ocul Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.ajo.2025.03.025_bib65","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ophtha.2014.11.022","article-title":"Impact of the introduction of generic latanoprost on glaucoma medication adherence","volume":"122","author":"Stein","year":"2015","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ajo.2025.03.025_bib66","doi-asserted-by":"crossref","first-page":"630","DOI":"10.18240\/ijo.2023.04.18","article-title":"Initial medication adherence in newly diagnosed glaucoma patients: three adherence measures","volume":"16","author":"Menino","year":"2023","journal-title":"Int J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ajo.2025.03.025_bib67","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/ceo.13524","article-title":"Real-world assessment of topical glaucoma medication persistence rates based on national pharmaceutical claim data in a defined population","volume":"47","author":"Zhu","year":"2019","journal-title":"Clin Experiment Ophthalmol"},{"key":"10.1016\/j.ajo.2025.03.025_bib68","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2147\/OPTH.S49467","article-title":"Patient adherence and persistence with topical ocular hypotensive therapy in real-world practice: A comparison of bimatoprost 0.01% and travoprost Z 0.004% ophthalmic solutions","volume":"8","author":"Campbell","year":"2014","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2025.03.025_bib69","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ogla.2020.04.007","article-title":"Inpatient adherence to topical glaucoma medications before and after an educational intervention","volume":"3","author":"Mammo","year":"2020","journal-title":"Ophthalmol Glaucoma"},{"issue":"2","key":"10.1016\/j.ajo.2025.03.025_bib70","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.amjopharm.2007.05.004","article-title":"Medication adherence and health care costs with the introduction of latanoprost therapy for glaucoma in a Medicare managed care population","volume":"5","author":"Bhosle","year":"2007","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.1016\/j.ajo.2025.03.025_bib0037","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2415-10-5","article-title":"Persistence on prostaglandin ocular hypotensive therapy: an assessment using medication possession and days covered on therapy","volume":"10","author":"Reardon","year":"2010","journal-title":"BMC Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2025.03.025_bib71","first-page":"728","article-title":"Comparing adherence and persistence across 6 chronic medication classes","volume":"15","author":"Yeaw","year":"2009","journal-title":"J Manag Care Spec Pharm"},{"issue":"9","key":"10.1016\/j.ajo.2025.03.025_bib72","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/IJG.0b013e3181f4661b","article-title":"Adherence to topical glaucoma medication during hospitalization","volume":"20","author":"Yousuf","year":"2011","journal-title":"J Glaucoma"},{"issue":"2","key":"10.1016\/j.ajo.2025.03.025_bib0036","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/0044011-200929020-00005","article-title":"Cost effectiveness of travoprost versus a fixed combination of latanoprost\/timolol in patients with ocular hypertension or glaucoma: analysis based on the UK general practitioner research database","volume":"29","author":"De Natale","year":"2009","journal-title":"Clin Drug Investig"},{"issue":"3","key":"10.1016\/j.ajo.2025.03.025_bib73","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/IJG.0b013e3181815421","article-title":"Determinants of adherence to glaucoma medical therapy in a long-term patient population","volume":"18","author":"Djafari","year":"2009","journal-title":"J Glaucoma"},{"issue":"5","key":"10.1016\/j.ajo.2025.03.025_bib74","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1038\/eye.2008.213","article-title":"Persistency with medical treatment for glaucoma and ocular hypertension in the United Kingdom: 1994\u20132005","volume":"23","author":"Owen","year":"2009","journal-title":"Eye"},{"issue":"9","key":"10.1016\/j.ajo.2025.03.025_bib0029","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/j.ophtha.2007.03.042","article-title":"Evaluation of practice patterns for the care of open-angle glaucoma compared with claims data: the glaucoma adherence and persistency study","volume":"114","author":"Quigley","year":"2007","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ajo.2025.03.025_bib76","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ajo.2003.10.035","article-title":"Patient persistency with topical ocular hypotensive therapy in a managed care population","volume":"137","author":"Reardon","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2025.03.025_bib77","first-page":"261","article-title":"Patient persistence with first-line antiglaucomatous monotherapy","volume":"4","author":"Arias","year":"2010","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2025.03.025_bib78","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1089\/jop.2004.20.383","article-title":"A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension","volume":"20","author":"Day","year":"2004","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.ajo.2025.03.025_bib79","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2174\/1874364101004010007","article-title":"Changes in trend of newly prescribed anti-glaucoma medications in recent nine years in a Japanese local community","volume":"4","author":"Kashiwagi","year":"2010","journal-title":"Open J Ophthalmol"},{"key":"10.1016\/j.ajo.2025.03.025_bib80","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s12325-017-0549-0","article-title":"Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: effectiveness and treatment persistence","volume":"34","author":"Kuwayama","year":"2017","journal-title":"Adv Ther"},{"issue":"20","key":"10.1016\/j.ajo.2025.03.025_bib81","doi-asserted-by":"crossref","first-page":"6166","DOI":"10.3390\/jcm11206166","article-title":"Evaluation of the efficacy duration of topical therapies in eyes with primary Open-Angle glaucoma","volume":"11","author":"Lanza","year":"2022","journal-title":"J Clin Med"},{"issue":"4","key":"10.1016\/j.ajo.2025.03.025_bib82","doi-asserted-by":"crossref","first-page":"e386","DOI":"10.1097\/IJG.0000000000000380","article-title":"The Maccabi Glaucoma Study: treatment patterns and persistence with glaucoma therapy in a large Israeli health maintenance organization","volume":"25","author":"Goldshtein","year":"2016","journal-title":"J Glaucoma"},{"issue":"1","key":"10.1016\/j.ajo.2025.03.025_bib83","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-040301","article-title":"Evaluation of early medication persistence with omidenepag isopropyl, a topical selective prostaglandin EP2 agonist, in patients with glaucoma: a retrospective two-institute study","volume":"11","author":"Nakakura","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.ajo.2025.03.025_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100916","article-title":"Inflammation in Glaucoma: from the back to the front of the eye, and beyond","volume":"83","author":"Baudouin","year":"2021","journal-title":"Prog Retin Eye Res"},{"issue":"3","key":"10.1016\/j.ajo.2025.03.025_bib0031","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1159\/000512924","article-title":"The minimal clinically important difference in glaucoma medication adherence: interviews of glaucoma experts","volume":"64","author":"Kolli","year":"2021","journal-title":"Ophthalmic Res"},{"issue":"9","key":"10.1016\/j.ajo.2025.03.025_bib0032","doi-asserted-by":"crossref","DOI":"10.2196\/13617","article-title":"Predicting dropouts from an electronic health platform for lifestyle interventions: analysis of methods and predictors","volume":"21","author":"Pedersen","year":"2019","journal-title":"J Med Internet Res"},{"key":"10.1016\/j.ajo.2025.03.025_bib0033","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2147\/PPA.S174922","article-title":"A theory-driven qualitative study exploring issues relating to adherence to topical glaucoma medications","volume":"13","author":"McDonald","year":"2019","journal-title":"Patient Prefer Adher"},{"key":"10.1016\/j.ajo.2025.03.025_bib0034","doi-asserted-by":"crossref","first-page":"6576","DOI":"10.34172\/ijhpm.2022.6576","article-title":"What makes people with chronic illnesses discontinue treatment? A practice theory informed analysis of adherence to treatment among patients with drug-resistant tuberculosis in Pakistan","volume":"12","author":"Abbas","year":"2023","journal-title":"Int J Health Policy Manag"},{"issue":"2","key":"10.1016\/j.ajo.2025.03.025_bib0038","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ophtha.2022.09.009","article-title":"Laser in Glaucoma and Ocular hypertension (LiGHT) trial: six-year results of primary selective Laser trabeculoplasty versus eye drops for the treatment of glaucoma and ocular hypertension","volume":"130","author":"Gazzard","year":"2023","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2025.03.025_bib0039","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1007\/s00417-021-05098-z","article-title":"10-year outcomes of first-line selective laser trabeculoplasty (SLT) for primary open-angle glaucoma (POAG)","volume":"259","author":"Ansari","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ajo.2025.03.025_bib0040","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ajo.2021.06.012","article-title":"Long-term outcomes of selective laser trabeculoplasty for open-angle glaucoma in the Caribbean","volume":"232","author":"Realini","year":"2021","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2025.03.025_bib0041","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1001\/jamaophthalmol.2021.2351","article-title":"Minimally invasive glaucoma surgical techniques for open-angle glaucoma: an overview of Cochrane systematic reviews and network meta-analysis","volume":"139","author":"Bicket","year":"2021","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"10.1016\/j.ajo.2025.03.025_bib0042","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183142","article-title":"Minimally-invasive glaucoma surgeries (MIGS) for open angle glaucoma: a systematic review and meta-analysis","volume":"12","author":"Lavia","year":"2017","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.ajo.2025.03.025_bib0043","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1007\/s40123-024-00984-1","article-title":"Ten-year effectiveness and safety of trabecular micro-bypass stent implantation with cataract surgery in patients with glaucoma or ocular hypertension","volume":"13","author":"Neuhann","year":"2024","journal-title":"Ophthalmol Ther"},{"issue":"1","key":"10.1016\/j.ajo.2025.03.025_bib0044","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40662-021-00263-1","article-title":"Long-term outcomes of two first-generation trabecular micro-bypass stents (iStent) with phacoemulsification in primary open-angle glaucoma: eight-year results","volume":"8","author":"Salimi","year":"2021","journal-title":"Eye Vis (Lond)"},{"issue":"4","key":"10.1016\/j.ajo.2025.03.025_bib0045","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s12325-024-02788-y","article-title":"Conrad-Hengerer I. 7-year efficacy and safety of iStent inject trabecular micro-bypass in combined and standalone usage","volume":"41","author":"Hengerer","year":"2024","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.ajo.2025.03.025_bib0046","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40265-023-01973-7","article-title":"Efficacy and safety of the travoprost intraocular implant in reducing topical IOP-lowering medication burden in patients with open-angle glaucoma or ocular hypertension","volume":"84","author":"Berdahl","year":"2024","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.ajo.2025.03.025_bib0047","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.ophtha.2020.06.018","article-title":"Phase 3, randomized, 20-month study of bimatoprost implant in open-angle glaucoma and ocular hypertension (ARTEMIS 1)","volume":"127","author":"Medeiros","year":"2020","journal-title":"Ophthalmology"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425001370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425001370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T03:56:19Z","timestamp":1777780579000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939425001370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":82,"alternative-id":["S0002939425001370"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2025.03.025","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adherence and Persistence on Prostaglandin Analogues for Glaucoma: A Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2025.03.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}